Financial Performance - Revenue for Q3 2021 was ¥86,458,898.73, a decrease of 26.63% compared to the same period last year[3] - Net profit attributable to shareholders was ¥4,888,094.18, down 68.37% year-on-year[3] - The company reported a net loss of CNY 24.53 million for Q3 2021, compared to a profit of CNY 25.99 million in the same quarter last year[21] - The net profit for Q3 2021 was -25,781,383.17 CNY, a significant decline compared to the net profit of 21,688,750.59 CNY in the same period last year[22] - The net profit attributable to the parent company was -22,781,213.47 CNY, compared to 21,751,604.18 CNY in Q3 2020[22] - Basic earnings per share were ¥0.0047, a decrease of 68.67% compared to the same period last year[3] - The basic and diluted earnings per share were both -0.0221 CNY, down from 0.0211 CNY in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities was -¥12,202,601.96, representing a decline of 114.84% compared to the previous year[9] - Cash received from operating activities decreased by 30.76% to ¥249,811,207.55 compared to the same period last year[9] - Cash flow from operating activities showed a net outflow of -12,202,601.96 CNY, a decrease from a net inflow of 82,254,593.09 CNY in Q3 2020[25] - Total cash inflow from operating activities was 265,224,529.22 CNY, down from 364,503,620.76 CNY in the same period last year[25] - Cash outflow from operating activities totaled 277,427,131.18 CNY, slightly lower than 282,249,027.67 CNY in Q3 2020[25] - The ending cash and cash equivalents balance was 38,157,174.12 CNY, a slight decrease from 38,417,040.81 CNY at the end of Q3 2020[26] - The company's cash and cash equivalents decreased from ¥54,591,460.06 at the end of 2020 to ¥38,157,174.12 by September 30, 2021, a decline of approximately 30%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥805,916,743.82, a decrease of 2.16% from the end of the previous year[3] - Total assets decreased to CNY 805.92 million, down from CNY 823.71 million year-over-year[19] - Current liabilities decreased to CNY 103.83 million, a reduction of 24.61% from CNY 137.66 million in the previous year[19] - Non-current liabilities increased to CNY 42.82 million, compared to CNY 1.00 million in the same period last year[19] - The company's total equity decreased to CNY 659.27 million, down from CNY 685.05 million year-over-year[19] - Total equity attributable to shareholders was ¥618,042,318.86, down 3.55% from the previous year[4] Research and Development - Research and development expenses increased by 110.55% to ¥59,102,128.14 due to new project expenditures[9] - Research and development expenses increased significantly to CNY 59.10 million, up 110.81% from CNY 28.07 million in the previous year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 118,448[11] - The largest shareholder, Wang Hongming, holds 14.00% of shares, totaling 144,138,394 shares[12] - The company has a total of 10 major shareholders, with the top three holding a combined 32.74% of shares[12] Legal Matters - The company has ongoing litigation with a total claim amounting to ¥266,767,130.02 related to investment losses[13] - The company is committed to timely information disclosure regarding ongoing litigation and other significant matters[14] Contracts and Projects - The company has completed construction work worth ¥28,337,500 under a contract with Shandong Zhongchuan, which was terminated in 2021[15] - The company has a contract with Shandong Zhongchuan for a total project amount of approximately ¥1 billion, with a minimum of ¥500 million allocated for landscaping[14] Operational Performance - The company reported a significant decrease in operating income due to the disposal of equity in Guangxi Intercontinental[9] - Total operating revenue for Q3 2021 was CNY 236.21 million, a decrease of 33.33% compared to CNY 354.41 million in the same period last year[21] - Total operating costs for Q3 2021 were CNY 262.76 million, down 18.99% from CNY 324.80 million year-over-year[21]
四环生物(000518) - 2021 Q3 - 季度财报